A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 679 participants.
Also called NCT05013229
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 679 participants
- Sponsor
- Registry
-
NCT05013229 -
2020-005309-18 -
jRCT2051210127
-
- Other papers using this trial's data
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Czechia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Poland, Slovenia, South Africa, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT05013229. Randomized; no masking; primary purpose treatment. Start 2021-11-30 (actual); primary completion 2023-11-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- IcoSema
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05013229- Content hash
fcd4cd6714d6f56bdd8078432a1f03bc96fce22e00774baf8ba9ff2e568bdd29